殷敏女士于2022年1月加入百济神州，担任百济神州大中华区首席商务官。殷敏女士拥有近二十年医药行业从业经验，对医疗健康领域的发展和特性有深刻的洞察。殷敏女士于2006年至2021年就职于阿斯利康，历任高级财务规划经理、海外区域市场战略项目负责人、中国/香港合规部副总裁、商业及多元化渠道部副总裁等多个重要岗位。2018年6月，殷敏女士被委任为阿斯利康中国副总裁，肿瘤业务部负责人，并于2019年1月升任阿斯利康中国肿瘤业务部总经理。殷敏女士毕业于上海交通大学，主修金融贸易以及计算机科学，于2002年获得中欧国际工商学院硕士学位。

Eva Yin joined BeiGene in 2022 as Chief Commercial Officer, BeiGene Greater China. Ms. Yin has nearly 20 years of experience in the pharmaceutical industry, having held various positions in finance, compliance, commercial & diversified channels, gaining insights into the development and characteristics of the healthcare industry.

Prior to BeiGene, Ms. Yin worked at AstraZeneca from 2006 to 2021, where she held various positions including Senior Business Finance Manager, Area Strategy Project Lead for International markets, Vice President of China & HK Compliance, and Vice President of Commercial & Diversified Channels. By Jan 2017, Eva expanded her responsibility to oversight of AstraZeneca HK & Macau. She was appointed AstraZeneca China Vice President, Oncology, in 2018, and promoted to General Manager of Oncology, AstraZeneca China, in 2019.

Ms. Yin graduated from Shanghai Jiao Tong University, majoring in finance & trading and computer science. She obtained her full-time MBA from CEIBS (China Europe International Business School) and completed an exchange program at London Business School in 2002.